SAN DIEGO, CA--(Marketwire - November 22, 2011) -
Highlighted Links |
Naviscan Website |
Naviscan Facebook |
The Naviscan PEM scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion, which facilitates early breast cancer diagnosis and assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions -- what researchers term "specificity."
"The Middle East, and Saudi Arabia in particular, is poised to be a major growth region for Naviscan. King Fahad is known throughout the Middle East to offer the latest in cutting edge technology and continues to do so with the addition of PEM," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and is globally distributed in 35 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.
About King Fahad Specialist Hospital Dammam (KFSH-D)
King Fahad Specialist Hospital Dammam (KFSH-D) is a tertiary referral hospital located in Dammam, Saudi Arabia. It is committed to serve the healthcare needs of the eastern province of Saudi Arabia with core competencies in Oncology, Transplant, Neurosciences, and Genetics.
Contact Information
Guillaume Bailliard
Executive Vice President
Naviscan, Inc.
Tel: +1.858.332.0941
Email Contact
Joleen Schultz
Naviscan Marketing Communications
321 Medical Launch
Tel: +1.858.455.5500
Email Contact